Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

Investors are expected to be cautious with CIPLA, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 4.239000
forwardPE 22.528801
debtToEquity 1.400000
earningsGrowth 0.301000
revenueGrowth 0.069000
grossMargins 0.671070
operatingMargins 0.186260
trailingEps 65.290000
forwardEps 63.540000

Cipla Limited's current ratio of 4.239 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, Cipla Limited can comfortably cover its liabilities, reflecting a strong financial outlook.
CIPLA's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
Cipla Limited's forward EPS being lower than its trailing EPS indicates that the company's earnings are projected to decrease. This suggests that Cipla Limited may struggle to maintain profitability at previous levels, potentially affecting its financial outlook.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

CIPLA's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect CIPLA to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


2 CIPLA sales were executed, with market price at 1590.4249877929688.Throughout the period under consideration, no sell transactions were recorded.The recent trend of more purchases than sales at Cipla Limited's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


CIPLA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see CIPLA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.